- Details
- (Length of Discussion: 12 min) A conversation between Petros Grivas and Alicia Morgans where they discuss the trials in the neoadjuvant, adjuvant and perioperative setting in advanced bladder cancer from ESMO 2018. They talk about the biology of the disease and considerations of available therapies, single vs combination, and for chemotherapy ineligible, as well as patients who opt out of chemothe...
|
- Details
- (Length of Discussion: 9 min) Alicia Morgans and Toni Choueiri provide a review of the historical background evolving from the era of targeted therapy to the current landscape in kidney cancer incorporating the surprising results from the CARMENA trial. Biographies: Toni K. Choueiri, MD, Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncol...
|
- Details
- (Length of Discussion: 7 min) Evan Yu and Alicia Morgans provide a review of bladder cancer prevalence and epidemiology in current clinical trials. This interview also includes the Keynote-057 trial results leading to plans for a phase 3 trial for a more efficacious treatment strategy for these patients with less toxicities. Biographies: Evan Yu, MD Alicia Morgans, MD, MPH Related Content: Pembrol...
|
- Details
- Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space. Monty explains the clinical applications, considering appropriate patient selection and toxicity profile relevant in decision making. Biographies: Sumanta (Monty) Kumar Pal, MD Charles J. Ryan, MD Related Content: Cabozantinib Versus Sunitinib As Initial Targeted Therapy f...
|
- Details
- Phillip Koo shares with Charles Ryan his perspective on bone health from the view of the nuclear radiologist discussing proper imaging techniques leading to an accurate categorization of types of fractures; pathologic, either tumor-driven or insufficiency fractures vs post-traumatic. Closing comments lead to the clinical responsibilities to incorporate from the ERA 223 data in hope to enhance pati...
|
- Details
- (Length of discussion: 21 minutes) Maria De Santis and Alicia Morgans review the role of chemotherapy in genitourinary malignancies. This discussion evolves to appropriate patient selection, sharing clinical preference in dosing chemotherapy and their view of supportive care. Biographies: Maria De Santis is a medical oncologist and Chair of Section for Interdisciplinary Genito-Urinary Cancer Medic...
|
- Details
- (Length of Discussion: 16 min) Arjun Balar and Alicia Morgans discuss outcomes in bladder cancer trials with a focus on primary endpoints, duration of response, and adverse events. Trials to practice with accurate clinical staging may lead to the ultimate goal of organ conservation in this patient population. Biographies: Arjun Balar, MD is the director of the genitourinary medical oncology progra...
|
- Details
- Misha Beltran and Alicia Morgans discuss treatment selection for patients with unique molecular subtypes. They discuss the use of ADT in this patient population as well as chemotherapy. Interestingly, they highlight the shared alteration and learnings from the study of small cell lung cancer. Biographies: Himisha Beltran, MD, Medical Oncologist, Dana Farber Cancer Institute, Harvard Medical School...
|
- Details
- (Length of Discussion: 10 min) Daniel George and Martin Voss discuss the evolving management of patients with advanced renal cell carcinoma with a focus on the genomic landscape in high risk localized disease. Based on molecular profiles, we may be able to prognosticate more accurately on their risk for recurrence. Applicability of this biomarker data will guide the future in appropriate therapeut...
|
- Details
- (Length of Discussion: 29 minutes) Alan Wein provides a presentation from the Société Internationale d'Urologie (SIU) 2018 meeting on nocturia. He defines nocturia highlighting the clinical implications to patients, related to frequency and bother. He reviews therapies and discusses management of these patients for practitioners to consider. Biography: Alan J. Wein, MD, Ph.D. (Hon). FACS, Surgeon,...
|
